» Articles » PMID: 20045147

Endogenous Red Blood Cell Membrane Fatty Acids and Sudden Cardiac Arrest

Abstract

Little is known of the associations of endogenous fatty acids with sudden cardiac arrest (SCA). We investigated the associations of SCA with red blood cell membrane fatty acids that are end products of de novo fatty acid synthesis: myristic acid (14:0), palmitic acid (16:0), palmitoleic acid (16:1 n7), vaccenic acid (18:1 n7), stearic acid (18:0), oleic acid (18:1 n9), and a related fatty acid, cis-7 hexadecenoic acid (16:1 n9). We used data from a population-based case-control study where cases, aged 25 to 74 years, were out-of-hospital SCA patients attended by paramedics in Seattle, WA (n = 265). Controls, matched to cases by age, sex, and calendar year, were randomly identified from the community (n = 415). All participants were free of prior clinically diagnosed heart disease. We observed associations of higher red blood cell membrane levels of 16:0, 16:1n-7, 18:1n-7, and 16:1n-9 with higher risk of SCA. In analyses adjusted for traditional SCA risk factors and trans- and n-3 fatty acids, a 1-SD-higher level of 16:0 was associated with 38% higher risk of SCA (odds ratio, 1.38; 95% confidence interval, 1.12-1.70) and a 1-SD-higher level of 16:1n-9 with 88% higher risk (odds ratio, 1.88; 95% confidence interval, 1.27-2.78). Several fatty acids that are end products of fatty acid synthesis are associated with SCA risk. Further work is needed to investigate if conditions that favor de novo fatty acid synthesis, such as high-carbohydrate/low-fat diets, might also increase the risk of SCA.

Citing Articles

Eicosapentaenoic Acid Rescues Cav1.2-L-Type Ca Channel Decline Caused by Saturated Fatty Acids via Both Free Fatty Acid Receptor 4-Dependent and -Independent Pathways in Cardiomyocytes.

Morishima M, Wang P, Horii K, Horikawa K, Ono K Int J Mol Sci. 2024; 25(14).

PMID: 39062812 PMC: 11276759. DOI: 10.3390/ijms25147570.


Circulating Omega-3 Polyunsaturated Fatty Acids Levels in Coronary Heart Disease: Pooled Analysis of 36 Observational Studies.

Xiao Y, Chen Y, Pietzner A, Elbelt U, Fan Z, Weylandt K Nutrients. 2024; 16(11).

PMID: 38892543 PMC: 11174367. DOI: 10.3390/nu16111610.


Potential Cardioprotective Effects and Lipid Mediator Differences in Long-Chain Omega-3 Polyunsaturated Fatty Acid Supplemented Mice Given Chemotherapy.

Angelotti A, Snoke D, Ormiston K, Cole R, Borkowski K, Newman J Metabolites. 2022; 12(9).

PMID: 36144189 PMC: 9505633. DOI: 10.3390/metabo12090782.


The mitochondrial calcium uniporter promotes arrhythmias caused by high-fat diet.

Joseph L, Reyes M, Homan E, Gowen B, Avula U, Goulbourne C Sci Rep. 2021; 11(1):17808.

PMID: 34497331 PMC: 8426388. DOI: 10.1038/s41598-021-97449-3.


Heart Rate Variability and Long Chain -3 Polyunsaturated Fatty Acids in Chronic Kidney Disease Patients on Haemodialysis: A Cross-Sectional Pilot Study.

Pinto A, MacLaughlin H, Hall W Nutrients. 2021; 13(7).

PMID: 34371962 PMC: 8308541. DOI: 10.3390/nu13072453.


References
1.
Retzlaff B, Dowdy A, Walden C, Bovbjerg V, Knopp R . The Northwest Lipid Research Clinic Fat Intake Scale: validation and utility. Am J Public Health. 1997; 87(2):181-5. PMC: 1380791. DOI: 10.2105/ajph.87.2.181. View

2.
Lee W, Lim S, Bassilian S, Bergner E, Edmond J . Fatty acid cycling in human hepatoma cells and the effects of troglitazone. J Biol Chem. 1998; 273(33):20929-34. DOI: 10.1074/jbc.273.33.20929. View

3.
Albert C, Campos H, Stampfer M, Ridker P, Manson J, Willett W . Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med. 2002; 346(15):1113-8. DOI: 10.1056/NEJMoa012918. View

4.
King I, Lemaitre R, Kestin M . Effect of a low-fat diet on fatty acid composition in red cells, plasma phospholipids, and cholesterol esters: investigation of a biomarker of total fat intake. Am J Clin Nutr. 2006; 83(2):227-36. DOI: 10.1093/ajcn/83.2.227. View

5.
Wang J, Zhang Y, Wang H, Han H, Nattel S, Yang B . Potential mechanisms for the enhancement of HERG K+ channel function by phospholipid metabolites. Br J Pharmacol. 2004; 141(4):586-99. PMC: 1574230. DOI: 10.1038/sj.bjp.0705646. View